Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA4 | P22748 | 3/20 | 0.38 |
| ▸ | CA5A | P35218 | 3/20 | 0.38 |
| ▸ | CA7 | P43166 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13337653 | 0.83 | CA12 (0.40) | CA12CA1CA2CA4CA5A | |
| SCHEMBL13337646 | 0.81 | KCNN4 (0.32) | TSHRPTPN1ALDH1A1KCNN4 | |
| SCHEMBL13366243 | 0.77 | NPSR1 (0.46) | TSHRACHEALDH1A1 | |
| SCHEMBL11773961 | 0.71 | HPGD (0.39) | CA12CA1CA2CA4CA5A | |
| SCHEMBL11348721 | 0.69 | CA2 (0.60) | CA12CA1CA2CA4CA5A | |
| SCHEMBL28661245 | 0.69 | MEN1 (0.53) | CA12CA1CA2CA4CA5A | |
| SCHEMBL13337660 | 0.67 | PTPN1 (0.44) | CA1CA2CA4CA5ACA9 | |
| SCHEMBL7067972 | 0.67 | CA2 (0.47) | CA12CA1CA2CA4CA5A | |
| SCHEMBL28459607 | 0.67 | CA12 (0.50) | CA12CA1CA2CA4CA5A | |
| SCHEMBL23037761 | 0.66 | TSHR (0.52) | CA12CA1CA2CA4CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709465-B2 | Phosphorous containing compounds including triphenylmethylphosphonate esters for the treatment of melanoma and other cancers | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709465-B2 | Phosphorous containing compounds including triphenylmethylphosphonate esters for the treatment of melanoma and other cancers | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-05-04 | — | — | US | disclosed |
| US-20090004293-A1 | Phosphorous Containing Compounds Including Triphenylmethylphosphonate Esters for the Treatment of Melanoma and Other Cancers | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2009-01-01 | — | — | US | disclosed |
| US-20090004293-A1 | Phosphorous Containing Compounds Including Triphenylmethylphosphonate Esters for the Treatment of Melanoma and Other Cancers | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2009-01-01 | — | — | US | disclosed |
| WO-2007137200-A2 | PHOSPHOROUS CONTAINING COMPOUNDS INCLUDING TRIPHENYLMETHYLPHOSPHONATE ESTERS FOR THE TREATMENT OF MELANOMA AND OTHER CANCERS | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090004293-A1 | Phosphorous Containing Compounds Including Triphenylmethylphosphonate Esters for the Treatment of Melanoma and Other Cancers | PHOSPHO1, MCL1, MTMR1 | CA12 1358/4885CA1 809/4885CA2 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.